Cornerstone Planning Group’s Pliant Therapeutics PLRX Stock Holding History

Cornerstone Planning Group’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24	Closed	-$264	–	1657
2024 Q4	$264	Buy	+24	New	+$328	﹤0.01%	1304
2024 Q1	–	Sell	-2	Closed	-$36	–	1174
2023 Q4	$36	Hold	2	–	–	﹤0.01%	931
2023 Q3	$35	Buy	+2	New	+$35	﹤0.01%	1159

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Cornerstone Planning Group's PLRX Position: Q1 2025 in Review

Cornerstone Planning Group sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 24 shares — an estimated $264 sold.

Cornerstone Planning Group first reported a position in PLRX in Q3 2023 and held it in 3 quarters. The position peaked at $264 in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

Cornerstone Planning Group reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
Cornerstone Planning Group sold 24 Pliant Therapeutics shares in Q1 2025, an estimated $264.
Cornerstone Planning Group first reported a position in Pliant Therapeutics in Q3 2023 and held it in 3 quarters.
Cornerstone Planning Group's Pliant Therapeutics position peaked at $264 in Q4 2024.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Cornerstone Planning Group's 13F filing for Q1 2025, filed 30 Apr 2025.